OBJECTIVE: This phase II study evaluated the efficacy and safety of pegylated liposomal doxorubicin (PLD) 30 to 35 mg/m(2) plus oxaliplatin 70 mg/m(2) every 28 days in women with advanced ovarian cancer that recurred or progressed after a platinum-based regimen. METHODS: 43 women received a median of 6 courses of treatment. RESULTS: Objective response was 54% in the evaluable population and was higher in women with platinum-sensitive (67%) compared with platinum-resistant disease (29%). At a median duration of follow-up of 15.5 months, median overall survival was 15.8 months and time to tumor progression 7.3 months. Most toxicity was no greater than grade 1 or 2. There was no grade 3 or 4 palmar-plantar erythrodysesthesia. After 264 cycles administered, neutropenia was the most common cause of severe toxicity and required one patient to withdraw from the study. No cardiotoxicity was reported. CONCLUSION: PLD plus oxaliplatin is active and well tolerated in women with relapsed advanced ovarian cancer, regardless of platinum sensitivity.
OBJECTIVE: This phase II study evaluated the efficacy and safety of pegylated liposomal doxorubicin (PLD) 30 to 35 mg/m(2) plus oxaliplatin 70 mg/m(2) every 28 days in women with advanced ovarian cancer that recurred or progressed after a platinum-based regimen. METHODS: 43 women received a median of 6 courses of treatment. RESULTS: Objective response was 54% in the evaluable population and was higher in women with platinum-sensitive (67%) compared with platinum-resistant disease (29%). At a median duration of follow-up of 15.5 months, median overall survival was 15.8 months and time to tumor progression 7.3 months. Most toxicity was no greater than grade 1 or 2. There was no grade 3 or 4 palmar-plantar erythrodysesthesia. After 264 cycles administered, neutropenia was the most common cause of severe toxicity and required one patient to withdraw from the study. No cardiotoxicity was reported. CONCLUSION: PLD plus oxaliplatin is active and well tolerated in women with relapsed advanced ovarian cancer, regardless of platinum sensitivity.
Authors: Sarah F Adams; Evelyn B Marsh; Wafic Elmasri; Steffanie Halberstadt; Stephanie Vandecker; Mary D Sammel; Angela R Bradbury; Mary Daly; Beth Karlan; Stephen C Rubin Journal: Gynecol Oncol Date: 2011-09-25 Impact factor: 5.482
Authors: Bhavana Pothuri; Allison L Brodsky; Joseph A Sparano; Stephanie V Blank; Mimi Kim; Dawn L Hershman; Amy Tiersten; Brian F Kiesel; Jan H Beumer; Leonard Liebes; Franco Muggia Journal: Cancer Chemother Pharmacol Date: 2020-02-13 Impact factor: 3.333
Authors: Kathleen A Griffith; Shijun Zhu; Meg Johantgen; Michael D Kessler; Cynthia Renn; Andreas S Beutler; Rahul Kanwar; Nicholas Ambulos; Guido Cavaletti; Jordi Bruna; Chiara Briani; Andreas A Argyriou; Haralabos P Kalofonos; Laura M Yerges-Armstrong; Susan G Dorsey Journal: J Pain Symptom Manage Date: 2017-07-23 Impact factor: 3.612
Authors: Sham S Kakar; Christopher A Worth; Zhenglong Wang; Kelsey Carter; Mariusz Ratajczak; Pranesh Gunjal Journal: J Cancer Stem Cell Res Date: 2016-04-19